Status:
COMPLETED
Study of Cyclosporine in Post-LASIK Patients
Lead Sponsor:
Allergan
Conditions:
Laser In Situ Keratomileusis
Eligibility:
All Genders
21-50 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.
Eligibility Criteria
Inclusion
- Patient is scheduled for bilateral LASIK surgery
- Patient is in good general health
- Eye glasses prescription of -1 to -8
Exclusion
- Significant Dry Eye
- Presence of eye disease
- Uncontrolled systemic disease
- Previous use of RESTASIS®
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
621 Patients enrolled
Trial Details
Trial ID
NCT00991458
Start Date
October 1 2009
End Date
April 1 2011
Last Update
July 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Overland Park, Kansas, United States